Lake Street Reaffirms Their Buy Rating on Augmedix (AUGX)

Lake Street analyst Brooks O’Neil maintained a Buy rating on Augmedix (AUGX – Research Report) today and set a price target of $8.00. The company’s shares closed yesterday at $4.18.

O’Neil covers the Healthcare sector, focusing on stocks such as Tandem Diabetes Care, Astrana Health, and Alphatec Holdings. According to TipRanks, O’Neil has an average return of 0.7% and a 46.08% success rate on recommended stocks.

Currently, the analyst consensus on Augmedix is a Strong Buy with an average price target of $6.00, a 43.54% upside from current levels. In a report released yesterday, B.Riley Financial also resumed coverage with a Buy rating on the stock with a $5.50 price target.

AUGX market cap is currently $203.7M and has a P/E ratio of -9.42.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Augmedix (AUGX) Company Description:

Augmedix Inc humanizes the clinician-patient experience by enabling clinicians to focus on what matters most, delivering high-quality patient care. It converts natural clinician-patient conversation into medical documentation and provides real-time administrative support, including referrals, orders, and reminders. The service, which supports over 35 specialties, delivers timely, accurate and comprehensive medical documentation to several of the healthcare systems in the U.S. and to hundreds of independent clinicians nationwide. Augmedix focuses on saving clinicians 2-3 hours per day, improve clinician productivity by as much as 20%, and increase clinicians’ satisfaction with work-life balance over 40%.